The Role of MA Modification in Autoimmunity: Emerging Mechanisms and Therapeutic Implications

Overview

Journal Clin Rev Allergy Immunol

Specialty Allergy & Immunology

Date 2025 Mar 14

PMID 40085180

Authors

Liyun Xu

Tian Shen

Yongzhen Li

Xiaochuan Wu

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (mA), a prevalent and essential RNA modification, serves a key function in driving autoimmune disease pathogenesis. By modulating immune cell development, activation, migration, and polarization, as well as inflammatory pathways, mA is crucial in forming innate defenses and adaptive immunity. This article provides a comprehensive overview of mA modification features and reveals how its dysregulation affects the intensity and persistence of immune responses, disrupts immune tolerance, exacerbates tissue damage, and promotes the development of autoimmunity. Specific examples include its contributions to systemic autoimmune disorders like lupus and rheumatoid arthritis, as well as conditions that targeting specific organs like multiple sclerosis and type 1 diabetes. Furthermore, this review explores the therapeutic promise of target mA-related enzymes ("writers," "erasers," and "readers") and summarizes recent advances in intervention strategies. By focusing on the mechanistic and therapeutic implications of mA modification, this review sheds light on its role as a promising tool for both diagnosis and treatment in autoimmune disorders, laying the foundation for advancements in customized medicine.

References

Xiao Z, Miller J, Zheng S . An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2020; 20(2):102743. DOI: 10.1016/j.autrev.2020.102743. View

Pisetsky D . Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023; 19(8):509-524. PMC: 10171171. DOI: 10.1038/s41581-023-00720-1. View

Cao F, Liu Y, Ni Q, Chen Y, Wan C, Liu S . Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019. Autoimmun Rev. 2023; 22(8):103359. DOI: 10.1016/j.autrev.2023.103359. View

Scherlinger M, Mertz P, Sagez F, Meyer A, Felten R, Chatelus E . Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. 2020; 19(6):102531. DOI: 10.1016/j.autrev.2020.102531. View

Conrad N, Misra S, Verbakel J, Verbeke G, Molenberghs G, Taylor P . Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023; 401(10391):1878-1890. DOI: 10.1016/S0140-6736(23)00457-9. View

Esteller M . Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-59. DOI: 10.1056/NEJMra072067. View

Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout 3rd W, Biniszkiewicz D . Epigenetic instability in ES cells and cloned mice. Science. 2001; 293(5527):95-7. DOI: 10.1126/science.1061402. View

Saini A, Ghoneim H, Lio C, Collins P, Oltz E . Gene Regulatory Circuits in Innate and Adaptive Immune Cells. Annu Rev Immunol. 2022; 40:387-411. PMC: 9241025. DOI: 10.1146/annurev-immunol-101320-025949. View

Liu Q, Zhu F, Liu X, Lu Y, Yao K, Tian N . Non-oxidative pentose phosphate pathway controls regulatory T cell function by integrating metabolism and epigenetics. Nat Metab. 2022; 4(5):559-574. DOI: 10.1038/s42255-022-00575-z. View

10.

Desrosiers R, Friderici K, Rottman F . Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974; 71(10):3971-5. PMC: 434308. DOI: 10.1073/pnas.71.10.3971. View

11.

Zhang C, Liu N . N6-methyladenosine (m6A) modification in gynecological malignancies. J Cell Physiol. 2022; 237(9):3465-3479. DOI: 10.1002/jcp.30828. View

12.

Zhang C, Chen L, Peng D, Jiang A, He Y, Zeng Y . METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation. Mol Cell. 2020; 79(3):425-442.e7. DOI: 10.1016/j.molcel.2020.06.017. View

13.

Li Y, Xia L, Tan K, Ye X, Zuo Z, Li M . N-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. Nat Genet. 2020; 52(9):870-877. DOI: 10.1038/s41588-020-0677-3. View

14.

Liu J, Dou X, Chen C, Chen C, Liu C, Xu M . -methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. Science. 2020; 367(6477):580-586. PMC: 7213019. DOI: 10.1126/science.aay6018. View

15.

Haussmann I, Bodi Z, Sanchez-Moran E, Mongan N, Archer N, Fray R . mA potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination. Nature. 2016; 540(7632):301-304. DOI: 10.1038/nature20577. View

16.

Lesbirel S, Wilson S . The mA‑methylase complex and mRNA export. Biochim Biophys Acta Gene Regul Mech. 2018; 1862(3):319-328. PMC: 6414750. DOI: 10.1016/j.bbagrm.2018.09.008. View

17.

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

18.

Meyer K . mA-mediated translation regulation. Biochim Biophys Acta Gene Regul Mech. 2018; 1862(3):301-309. PMC: 6401301. DOI: 10.1016/j.bbagrm.2018.10.006. View

19.

Roignant J, Soller M . mA in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression. Trends Genet. 2017; 33(6):380-390. DOI: 10.1016/j.tig.2017.04.003. View

20.

Boo S, Kim Y . The emerging role of RNA modifications in the regulation of mRNA stability. Exp Mol Med. 2020; 52(3):400-408. PMC: 7156397. DOI: 10.1038/s12276-020-0407-z. View